{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"90.3","value":"19.5"},{"groupId":"OG001","spread":"70.6","value":"23.8"},{"groupId":"OG002","spread":"60.8","value":"22.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"Outcome data are the trough plasma concentrations of afatinib at day 29 after multiple daily dosing of 40mg afatinib and after dose escalation to 50mg or dose reduction to 30mg afatinib (no patient dose reduced to 20mg during the PK assessment period).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients receiving Afatinib 30mg once daily (q.d.) after a dose reduction.","id":"OG000","title":"Afatinib 30mg q.d."},{"description":"Patients receiving Afatinib 40mg once daily (q.d.)","id":"OG001","title":"Afatinib 40mg q.d."},{"description":"Patients receiving Afatinib 50mg once daily (q.d.) after a dose escalation.","id":"OG002","title":"Afatinib 50mg q.d."}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All patients who had at least 1 afatinib dose and who had at least 1 valid afatinib plasma concentration available.","reportingStatus":"POSTED","timeFrame":"Day 29 (course 2, visit 2)","title":"Pharmacokinetics of Afatinib at Day 29","type":"SECONDARY","unitOfMeasure":"ng/mL"}